Mereo BioPharma Group plc

Mereo BioPharma Group plc a biopharmaceutical company develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate etigilimab (OMP-313M32) an antibody T-cell immunoreceptor with Ig and ITIM domains which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83) which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197) a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649) an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition it develops rare disease product candidates including Setrusumab (BPS-804) a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966) an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate etigilimab; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London the United Kingdom.